R-ESHAP as salvage therapy in patients with relapsed or refractory diffuse large B-cell lymphoma: A prospective phase II study. This is an ASCO Meeting Abstract from the 2011 ASCO Annual Meeting I.

In the new WHO–European Organisation for Research and Treatment of Cancer (WHO-EORTC) classification for cutaneous lymphomas three major groups of primary cutaneous B-cell lymphoma (CBCL) are ...

A new statistical analysis of patients with follicular lymphoma, made possible by 15 years of follow-up data from a SWOG and ...

AYA lymphoma patients often experience delayed diagnosis due to transitional life stages and lack of primary care or insurance. Lymphoma types and presentations in AYAs differ from those in children ...

Please provide your email address to receive an email when new articles are posted on . Circulating tumor DNA can be readily detected in patients with central nervous system lymphoma and may be a ...

Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS), is a rare subtype of non-Hodgkin lymphoma that frequently presents with multiorgan involvement. We report a diagnostically challenging ...

Arima Genomics, Inc., a company leveraging whole-genome sequence and structure information to provide comprehensive cancer ...

Enhancer hijacking emerges as a major “missing driver” mechanism in LBCL/PCN, enabling detection of non-chimeric oncogene activation such as IGL::BCL2, IGH::CCND2, and MAFA/MAFB rearrangements.

Burkitt lymphoma is an aggressive cancer that starts in B cells, which are part of the immune system. It can lead to death, but intensive treatment can improve the likelihood of long-term survival. In ...